Ozagrel hydrochloride, a selective thromboxane A2 synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice

BMC Gastroenterology

Volumn 13, Issue 1, 2013, Pages

  Tomishima, Yoshiro ^a   Ishitsuka, Yoichi ^a   Matsunaga, Naoya ^b   Nagatome, Minako ^a   Furusho, Hirokazu ^a   Irikura, Mitsuru ^a   Ohdo, Shigehiro ^b   Irie, Tetsumi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CCAAT ENHANCER BINDING PROTEIN; CYTOCHROME P450 2E1; GLUTATHIONE; MESSENGER RNA; N ACETYL 1,4 BENZOQUINONE IMINE; OZAGREL; PARACETAMOL; PROTEIN FOS;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; ENZYME ACTIVITY; HISTOPATHOLOGY; LIVER HEMORRHAGE; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; LIVER TOXICITY; MALE; MICROSOME; MOUSE; NONHUMAN; PROTEIN CONTENT; PROTEIN DEPLETION; PROTEIN EXPRESSION; RAT;

ACETAMINOPHEN; ALANINE TRANSAMINASE; ANIMALS; DISEASE MODELS, ANIMAL; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; GLUTATHIONE; INJECTIONS, INTRAPERITONEAL; LIVER; MALE; METHACRYLATES; MICE; MICE, INBRED ICR; THROMBOXANE-A SYNTHASE; TREATMENT OUTCOME;

EID: 84873029491     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-13-21     Document Type: Article

References (51)

1. Graham GG, Scott KF, Day RO. Tolerability of paracetamol. Drug Saf 2005, 28(3):227-240. 10.2165/00002018-200528030-00004, 15733027.
2. Li C, Martin BC. Trends in emergency department visits attributable to acetaminophen overdoses in the United States: 1993-2007. Pharmacoepidemiol Drug Saf 2011, 20(8):810-818. 10.1002/pds.2103, 21796717.
3. Craig DG, Bates CM, Davidson JS, Martin KG, Hayes PC, Simpson KJ. Overdose pattern and outcome in paracetamol-induced acute severe hepatotoxicity. Br J Clin Pharmacol 2011, 71(2):273-282. 10.1111/j.1365-2125.2010.03819.x, 3040549, 21219409.
4. Gow PJ, Jones RM, Dobson JL, Angus PW. Etiology and outcome of fulminant hepatic failure managed at an Australian liver transplant unit. J Gastroenterol Hepatol 2004, 19(2):154-159. 10.1111/j.1440-1746.2004.03273.x, 14731124.
5. Wei G, Bergquist A, Broomé U, Lindgren S, Wallerstedt S, Almer S, Sangfelt P, Danielsson A, Sandberg-Gertzén H, Lööf L, et al. Acute liver failure in Sweden: etiology and outcome. J Intern Med 2007, 262(3):393-401. 10.1111/j.1365-2796.2007.01818.x, 17697161.
6. Gyamlani GG, Parikh CR. Acetaminophen toxicity: suicidal vs. accidental. Crit Care 2002, 6(2):155-159. 10.1186/cc1475, 111182, 11983042.
7. Bechmann LP, Jochum C, Kocabayoglu P, Sowa JP, Kassalik M, Gieseler RK, Saner F, Paul A, Trautwein C, Gerken G, et al. Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol 2010, 53(4):639-647. 10.1016/j.jhep.2010.04.029, 20630612.
8. Antoine DJ, Jenkins RE, Dear JW, Williams DP, McGill MR, Sharpe MR, Craig DG, Simpson KJ, Jaeschke H, Park BK. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol 2012, 56(5):1070-1079. 10.1016/j.jhep.2011.12.019, 22266604.
9. Raucy JL, Lasker JM, Lieber CS, Black M. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys 1989, 271(2):270-283.
10. Patten CJ, Thomas PE, Guy RL, Lee M, Gonzalez FJ, Guengerich FP, Yang CS. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol 1993, 6(4):511-518. 10.1021/tx00034a019, 8374050.
11. Lee SS, Buters JT, Pineau T, Fernandez-Salguero P, Gonzalez FJ. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 1996, 271(20):12063-12067. 10.1074/jbc.271.20.12063, 8662637.
12. Gonzalez FJ. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res 2005, 569(1-2):101-110.
13. Hanawa N, Shinohara M, Saberi B, Gaarde WA, Han D, Kaplowitz N. Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. J Biol Chem 2008, 283(20):13565-13577. 10.1074/jbc.M708916200, 2376214, 18337250.
14. Hinson JA, Pike SL, Pumford NR, Mayeux PR. Nitrotyrosine-protein adducts in hepatic centrilobular areas following toxic doses of acetaminophen in mice. Chem Res Toxicol 1998, 11(6):604-607. 10.1021/tx9800349, 9625727.
15. LoGuidice A, Boelsterli UA. Acetaminophen overdose-induced liver injury in mice is mediated by peroxynitrite independently of the cyclophilin D-regulated permeability transition. Hepatology 2011, 54(3):969-978. 10.1002/hep.24464, 21626531.
16. James LP, McCullough SS, Lamps LW, Hinson JA. Effect of N-acetylcysteine on acetaminophen toxicity in mice: relationship to reactive nitrogen and cytokine formation. Toxicol Sci 2003, 75(2):458-467. 10.1093/toxsci/kfg181, 12883092.
17. Masubuchi Y, Suda C, Horie T. Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J Hepatol 2005, 42(1):110-116. 10.1016/j.jhep.2004.09.015, 15629515.
18. Masubuchi Y, Sugiyama S, Horie T. Th1/Th2 cytokine balance as a determinant of acetaminophen-induced liver injury. Chem Biol Interact 2009, 179(2-3):273-279.
19. Jaeschke H, Williams CD, Ramachandran A, Bajt ML. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int 2012, 32(1):8-20. 10.1111/j.1478-3231.2011.02501.x, 21745276.
20. Culo F, Renić M, Sabolović D, Rados M, Bilić A, Jagić V. Ketoconazole inhibits acetaminophen-induced hepatotoxicity in mice. Eur J Gastroenterol Hepatol 1995, 7(8):757-762.
21. North TE, Babu IR, Vedder LM, Lord AM, Wishnok JS, Tannenbaum SR, Zon LI, Goessling W. PGE2-regulated wnt signaling and N-acetylcysteine are synergistically hepatoprotective in zebrafish acetaminophen injury. Proc Natl Acad Sci USA 2010, 107(40):17315-17320. 10.1073/pnas.1008209107, 2951415, 20855591.
22. Rolin S, Masereel B, Dogné JM. Prostanoids as pharmacological targets in COPD and asthma. Eur J Pharmacol 2006, 533(1-3):89-100.
23. Ishitsuka Y, Moriuchi H, Isohama Y, Tokunaga H, Hatamoto K, Kurita S, Irikura M, Iyama K, Irie T. A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs. J Pharmacol Sci 2009, 111(2):211-215. 10.1254/jphs.09128SC, 19783866.
24. Xavier FE, Blanco-Rivero J, Sastre E, Badimón L, Balfagón G. Simultaneous inhibition of TXA(2) and PGI(2) synthesis increases NO release in mesenteric resistance arteries from cirrhotic rats. Clin Sci (Lond) 2010, 119(7):283-292.
25. Watson S, Daly M, Dawood B, Gissen P, Makris M, Mundell S, Wilde J, Mumford A. Phenotypic approaches to gene mapping in platelet function disorders - identification of new variant of P2Y12, TxA2 and GPVI receptors. Hämostaseologie 2010, 30(1):29-38.
26. Cavar I, Kelava T, Vukojević K, Saraga-Babić M, Culo F. The role of prostaglandin E2 in acute acetaminophen hepatotoxicity in mice. Histol Histopathol 2010, 25(7):819-830.
27. Cavar I, Kelava T, Heinzel R, Culo F. The role of prostacyclin in modifying acute hepatotoxicity of acetaminophen in mice. Coll Antropol 2009, 33(Suppl 2):25-29.
28. Reilly TP, Brady JN, Marchick MR, Bourdi M, George JW, Radonovich MF, Pise-Masison CA, Pohl LR. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol 2001, 14(12):1620-1628. 10.1021/tx0155505, 11743745.
29. Guarner F, Boughton-Smith NK, Blackwell GJ, Moncada S. Reduction by prostacyclin of acetaminophen-induced liver toxicity in the mouse. Hepatology 1988, 8(2):248-253. 10.1002/hep.1840080210, 3281885.
30. Baciewicz AM, Baciewicz FA. Ketoconazole and fluconazole drug interactions. Arch Intern Med 1993, 153(17):1970-1976. 10.1001/archinte.1993.00410170042004, 8357281.
31. Nakazawa M, Iizuka K, Ujiie A, Hiraku S, Ohki S. [Research and development of ozagrel, a highly selective inhibitor of TXA2 synthase]. Yakugaku Zasshi 1994, 114(12):911-933.
32. Dogné JM, de Leval X, Benoit P, Delarge J, Masereel B. Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. Am J Respir Med 2002, 1(1):11-17. 10.1007/BF03257158, 14720071.
33. Ishitsuka Y, Moriuchi H, Hatamoto K, Yang C, Takase J, Golbidi S, Irikura M, Irie T. Involvement of thromboxane A2 (TXA2) in the early stages of oleic acid-induced lung injury and the preventive effect of ozagrel, a TXA2 synthase inhibitor, in guinea-pigs. J Pharm Pharmacol 2004, 56(4):513-520. 10.1211/0022357023150, 15099446.
34. Matsunaga N, Nakamura N, Yoneda N, Qin T, Terazono H, To H, Higuchi S, Ohdo S. Influence of feeding schedule on 24-h rhythm of hepatotoxicity induced by acetaminophen in mice. J Pharmacol Exp Ther 2004, 311(2):594-600. 10.1124/jpet.104.069062, 15205452.
35. Latchoumycandane C, Goh CW, Ong MM, Boelsterli UA. Mitochondrial protection by the JNK inhibitor leflunomide rescues mice from acetaminophen-induced liver injury. Hepatology 2007, 45(2):412-421. 10.1002/hep.21475, 17366662.
36. Reisman SA, Buckley DB, Tanaka Y, Klaassen CD. CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes. Toxicol Appl Pharmacol 2009, 236(1):109-114. 10.1016/j.taap.2008.12.024, 2680225, 19371629.
37. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964, 239:2370-2378.
38. Kondo Y, Ishitsuka Y, Kadowaki D, Nagatome M, Saisho Y, Kuroda M, Hirata S, Irikura M, Hamasaki N, Irie T. Phosphoenolpyruvic acid, an intermediate of glycolysis, attenuates cellular injury induced by hydrogen peroxide and 2-deoxy-D-glucose in the porcine proximal kidney tubular cell line, LLC-PK 1. J Heal Sci 2010, 56(6):727-732.
39. Kondo Y, Ishitsuka Y, Kadowaki D, Kuroda M, Tanaka Y, Nagatome M, Irikura M, Hirata S, Sato K, Maruyama T, et al. Phosphoenolpyruvic acid, an intermediary metabolite of glycolysis, as a potential cytoprotectant and anti-oxidant in HeLa cells. Biol Pharm Bull 2012, 35(4):606-611. 10.1248/bpb.35.606, 22466568.
40. Yoshimi Y, Fujimura M, Myou S, Tachibana H, Hirose T. Effect of thromboxane A2 (TXA2) synthase inhibitor and TXA2 receptor antagonist alone and in combination on antigen-induced bronchoconstriction in guinea pigs. Prostaglandins Other Lipid Mediat 2001, 65(1):1-9. 10.1016/S0090-6980(01)00099-5, 11352222.
41. Sasaki K, Miyake H, Kinoshita T, Ikeyama S, Tashiro S. Protective effect of FK506 and thromboxane synthase inhibitor on ischemia-reperfusion injury in non-heart-beating donor in rat orthotopic liver transplantation. J Med Invest 2004, 51(1-2):76-83.
42. Xu H, Lee CY, Clemens MG, Zhang JX. Inhibition of TXA synthesis with OKY-046 improves liver preservation by prolonged hypothermic machine perfusion in rats. J Gastroenterol Hepatol 2008, 23(7 Pt 2):e212-e220.
43. Beyer RP, Fry RC, Lasarev MR, McConnachie LA, Meira LB, Palmer VS, Powell CL, Ross PK, Bammler TK, Bradford BU, et al. Multicenter study of acetaminophen hepatotoxicity reveals the importance of biological endpoints in genomic analyses. Toxicol Sci 2007, 99(1):326-337. 10.1093/toxsci/kfm150, 17562736.
44. Nakagawa H, Maeda S, Hikiba Y, Ohmae T, Shibata W, Yanai A, Sakamoto K, Ogura K, Noguchi T, Karin M, et al. Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology 2008, 135(4):1311-1321. 10.1053/j.gastro.2008.07.006, 18700144.
45. Nagy G, Kardon T, Wunderlich L, Szarka A, Kiss A, Schaff Z, Bánhegyi G, Mandl J. Acetaminophen induces ER dependent signaling in mouse liver. Arch Biochem Biophys 2007, 459(2):273-279. 10.1016/j.abb.2006.11.021, 17207453.
46. Badmann A, Keough A, Kaufmann T, Bouillet P, Brunner T, Corazza N. Role of TRAIL and the pro-apoptotic Bcl-2 homolog Bim in acetaminophen-induced liver damage. Cell Death Dis 2011, 2:e171. 10.1038/cddis.2011.55, 3168997, 21654829.
47. Wiggins CM, Tsvetkov P, Johnson M, Joyce CL, Lamb CA, Bryant NJ, Komander D, Shaul Y, Cook SJ. BIM(EL), an intrinsically disordered protein, is degraded by 20S proteasomes in the absence of poly-ubiquitylation. J Cell Sci 2011, 124(Pt 6):969-977.
48. Hinds MG, Smits C, Fredericks-Short R, Risk JM, Bailey M, Huang DC, Day CL. Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death Differ 2007, 14(1):128-136. 10.1038/sj.cdd.4401934, 16645638.
49. Bantel H, Schulze-Osthoff K. Mechanisms of cell death in acute liver failure. Front Physiol 2012, 3:79. 3317271, 22485095.
50. Saito C, Zwingmann C, Jaeschke H. Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine. Hepatology 2010, 51(1):246-254. 10.1002/hep.23267, 2977522, 19821517.
51. Gunawan BK, Liu ZX, Han D, Hanawa N, Gaarde WA, Kaplowitz N. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 2006, 131(1):165-178. 10.1053/j.gastro.2006.03.045, 16831600.